Zydus Cadila gets final approval for two drugs from USFDA
DSIJ Intelligence / 01 Aug 2017
Zydus Cadila has received final approval from the USFDA to market Temozolomide Capsules in strengths of 5 mg, 20 mg, 140 mg and 180 mg.
Zydus Cadila has received final approval from the USFDA to market Temozolomide Capsules in strengths of 5 mg, 20 mg, 140 mg and 180 mg.
Temozolomide Capsules is a chemotherapy drug used in management of brain tumors. The sales of Temozolomide are estimated at USD 100.4 million.
The group has also received the final approval from the USFDA to market Nadolol Tablets USP, 20 mg, 40 mg and 80 mg. Nadolol is used in management of hypertension and chest pain. The sales of Nadolol Tablets are estimated at USD 109.8 million.
Both the drugs will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad.
The group has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.